Erik Blazic
Erik Blazic
Contributor, The Yuan

Partner at Kearney.

(Bio)pharmas must advance more inclusive social agendas to build trust
(Bio)pharma firms are well positioned to ensure equal access to treatment by fostering patient trust via equity-focused drug discovery, clinical trials, commercial strategy, and healthcare ecosystem enablement, argue four healthcare executives with global management firm Kearney.